Abstract
Pheochromocytomas and extra-adrenal sympathetic paragangliomas are catecholamine-secreting neuroendocrine tumors derived from the chromaffin cells of the embryonic neural crest. Parasympathetic paragangliomas are related tumors which most often arise within the head and neck, and are anatomically associated with the parasympathetic nervous system. Patients with pheochromocytomas and extra-adrenal sympathetic paragangliomas generally present with symptoms resulting from excessive production and secretion of catecholamines whereas parasympathetic paragangliomas usually present as a solitary and progressively enlarging mass without catecholamine secretion.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Ronald A Delellis (2004) WHO histological classification of tumours of the adrenal gland. IARC Press, Lyon
Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT (1983) Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58(12):802–804
Fernandez-Calvet L, Garcia-Mayor RV (1994) Incidence of pheochromocytoma in South Galicia, Spain. J Intern Med 236(6):675–677
Stenstrom G, Svardsudd K (1986) Pheochromocytoma in Sweden 1958–1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220(3):225–232
McNeil AR, Blok BH, Koelmeyer TD, Burke MP, Hilton JM (2000) Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 30(6):648–652
Lo CY, Lam KY, Wat MS, Lam KS (2000) Adrenal pheochromocytoma remains a frequently overlooked diagnosis. Am J Surg 179(3):212–215
Ariton M, Juan CS, AvRuskin TW (2000) Pheochromocytoma: clinical observations from a Brooklyn tertiary hospital. Endocr Pract 6(3):249–252
Omura M, Saito J, Yamaguchi K, Kakuta Y, Nishikawa T (2004) Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27(3):193–202
Goldstein RE, O’Neill JA Jr, Holcomb GW, 3rd et al (1999) Clinical experience over 48 years with pheochromocytoma. Ann Surg 229(6):755–764; discussion 764–756
Kaufman BH, Telander RL, van Heerden JA, Zimmerman D, Sheps SG, Dawson B (1983) Pheochromocytoma in the pediatric age group: current status. J Pediatr Surg 18(6):879–884
Glibert SF (2000) Developmental Biology. In: Glibert SF (ed) Developmental Biology, 6th edn. Sinauer Associates Inc, Sunderland, Massachusetts
Lack E (1997) Tumors of the adrenal gland and extra-adrenal paraganglia. Atlas of tumor pathology, vol 3. Armed Forces Institute of Pathology, Washington, DC
Komminoth P, de Krijger R, Tischler A (2002) Paraganlia and the adrenal medulla. In: LiVolsi V, Asa S (eds) Endocrine pathology. Churchill Livingstone, Philadelphia, pp 149–169
McNicol AM, Young WF, Kawashima A, Komminoth P, Tischler AS (2004) Benign phaeochromocytoma. In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds) WHO classification of tumours – pathology and genetics of tumours of endocrine organs. IARC Press, Lyon, pp 151–155
Demeure MJ (1993) Physiology of the APUD system. Semin Surg Oncol 9(5):362–367
Eisenhofer G, Walther MM, Huynh TT et al (2001) Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab 86(5):1999–2008
Eisenhofer G, Keiser H, Friberg P et al (1998) Plasma metanephrines are markers of pheochromocytoma produced by catechol-O-methyltransferase within tumors. J Clin Endocrinol Metab 83(6):2175–2185
Grossman A, Pacak K, Sawka A et al (2006) Biochemical diagnosis and localization of pheochromocytoma: can we reach a consensus? Ann N Y Acad Sci 1073:332–347
Bravo EL, Tagle R (2003) Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24(4):539–553
Adler JT, Meyer-Rochow GY, Chen H et al (2008) Pheochromocytoma: current approaches and future directions. Oncologist 13(7):779–793
Bravo EL (2002) Pheochromocytoma: an approach to antihypertensive management. Ann N Y Acad Sci 970:1–10
Lee JA, Zarnegar R, Shen WT, Kebebew E, Clark OH, Duh QY (2007) Adrenal incidentaloma, borderline elevations of urine or plasma metanephrine levels, and the “subclinical” pheochromocytoma. Arch Surg 142(9):870–873; discussion 873–874
Kasperlik-Zeluska AA, Roslonowska E, Slowinska-Srzednicka J et al (1997) Incidentally discovered adrenal mass (incidentaloma): investigation and management of 208 patients. Clin Endocrinol (Oxf) 46(1):29–37
Stein PP, Black HR (1991) A simplified diagnostic approach to pheochromocytoma. A review of the literature and report of one institution’s experience. Medicine (Baltimore) 70(1):46–66
Bravo EL (2004) Pheochromocytoma: current perspectives in the pathogenesis, diagnosis, and management. Arq Bras Endocrinol Metabol 48(5):746–750
Eisenhofer G, Rivers G, Rosas AL, Quezado Z, Manger WM, Pacak K (2007) Adverse drug reactions in patients with phaeochromocytoma: incidence, prevention and management. Drug Saf 30(11):1031–1062
Taylor MJ, McIndoe A (2007) Unresponsive asystolic cardiac arrest responding to external cardiac pacing in a patient with phaeochromocytoma. Anaesthesia 62(8):838–841
Londe S (1978) Causes of hypertension in the young. Pediatr Clin North Am 25(1):55–65
De Krijger RR, Petri BJ, Van Nederveen FH et al (2006) Frequent genetic changes in childhood pheochromocytomas. Ann N Y Acad Sci 1073:166–176
Beltsevich DG, Kuznetsov NS, Kazaryan AM, Lysenko MA (2004) Pheochromocytoma surgery: epidemiologic peculiarities in children. World J Surg 28(6):592–596
Havekes B, Romijn JA, Eisenhofer G, Adams K, Pacak K (2009) Update on pediatric pheochromocytoma. Pediatr Nephrol 24(5):943–950
Whalen RK, Althausen AF, Daniels GH (1992) Extra-adrenal pheochromocytoma. J Urol 147(1):1–10
Neumann HP, Bausch B, McWhinney SR et al (2002) Germ-line mutations in nonsyndromic pheochromocytoma. N Engl J Med 346(19):1459–1466
Pomares FJ, Canas R, Rodriguez JM, Hernandez AM, Parrilla P, Tebar FJ (1998) Differences between sporadic and multiple endocrine neoplasia type 2A phaeochromocytoma. Clin Endocrinol (Oxf) 48(2):195–200
Walther MM, Reiter R, Keiser HR et al (1999) Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma. J Urol 162(3 Pt 1):659–664
Bornstein SR, Gimenez-Roqueplo AP (2006) Genetic testing in pheochromocytoma: increasing importance for clinical decision making. Ann N Y Acad Sci 1073:94–103
Loh KC, Fitzgerald PA, Matthay KK, Yeo PP, Price DC (1997) The treatment of malignant pheochromocytoma with iodine-131 metaiodobenzylguanidine (131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20(11):648–658
Plouin PF, Chatellier G, Fofol I, Corvol P (1997) Tumor recurrence and hypertension persistence after successful pheochromocytoma operation. Hypertension 29(5):1133–1139
Tischler AS (2008) Pheochromocytoma and extra-adrenal paraganglioma: updates. Arch Pathol Lab Med 132(8):1272–1284
Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB (2007) The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14(3):569–585
Shen WT, Sturgeon C, Clark OH, Duh QY, Kebebew E (2004) Should pheochromocytoma size influence surgical approach? A comparison of 90 malignant and 60 benign pheochromocytomas. Surgery 136(6):1129–1137
van der Harst E, de Herder WW, de Krijger RR et al (2002) The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147(1):85–94
Helman LJ, Cohen PS, Averbuch SD, Cooper MJ, Keiser HR, Israel MA (1989) Neuropeptide Y expression distinguishes malignant from benign pheochromocytoma. J Clin Oncol 7(11):1720–1725
Linnoila RI, Keiser HR, Steinberg SM, Lack EE (1990) Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol 21(11):1168–1180
Gimenez-Roqueplo AP, Favier J, Rustin P et al (2003) Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63(17):5615–5621
Brouwers FM, Eisenhofer G, Tao JJ et al (2006) High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91(11):4505–4509
Eisenhofer G, Bornstein SR, Brouwers FM et al (2004) Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 11(3):423–436
Amar L, Bertherat J, Baudin E et al (2005) Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23(34):8812–8818
Thompson LD (2002) Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases. Am J Surg Pathol 26(5):551–566
Strong VE, Kennedy T, Al-Ahmadie H et al (2008) Prognostic indicators of malignancy in adrenal pheochromocytomas: clinical, histopathologic, and cell cycle/apoptosis gene expression analysis. Surgery 143(6):759–768
Brouwers FM, Petricoin EF 3rd, Ksinantova L et al (2005) Low molecular weight proteomic information distinguishes metastatic from benign pheochromocytoma. Endocr Relat Cancer 12(2):263–272
John H, Ziegler WH, Hauri D, Jaeger P (1999) Pheochromocytomas: can malignant potential be predicted? Urology 53(4):679–683
Sisson JC, Shulkin BL, Esfandiari NH (2006) Courses of malignant pheochromocytoma: implications for therapy. Ann N Y Acad Sci 1073:505–511
Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K (2008) Current progress and future challenges in the biochemical diagnosis and treatment of pheochromocytomas and paragangliomas. Horm Metab Res 40(5):329–337
Lenders JW, Eisenhofer G, Mannelli M, Pacak K (2005) Phaeochromocytoma. Lancet 366(9486):665–675
Abe M, Orita Y, Nakashima Y, Nakamura M (1984) Hypertensive crisis induced by metoclopramide in patient with pheochromocytoma. Angiology 35(2):122–128
Lawrence AM (1967) Glucagon provocative test for pheochromocytoma. Ann Intern Med 66(6):1091–1096
Eisenhofer G, Goldstein DS, Walther MM et al (2003) Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test results. J Clin Endocrinol Metab 88(6):2656–2666
Sjoberg RJ, Simcic KJ, Kidd GS (1992) The clonidine suppression test for pheochromocytoma. A review of its utility and pitfalls. Arch Intern Med 152(6):1193–1197
Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89(2):479–491
Maurea S, Cuocolo A, Reynolds JC, Neumann RD, Salvatore M (1996) Diagnostic imaging in patients with paragangliomas. Computed tomography, magnetic resonance and MIBG scintigraphy comparison. Q J Nucl Med 40(4):365–371
Sahdev A, Sohaib A, Monson JP, Grossman AB, Chew SL, Reznek RH (2005) CT and MR imaging of unusual locations of extra-adrenal paragangliomas (pheochromocytomas). Eur Radiol 15(1):85–92
Van Der Horst-Schrivers AN, Jager PL, Boezen HM, Schouten JP, Kema IP, Links TP (2006) Iodine-123 metaiodobenzylguanidine scintigraphy in localising phaeochromocytomas – experience and meta-analysis. Anticancer Res 26(2B):1599–1604
Ilias I, Yu J, Carrasquillo JA et al (2003) Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88(9):4083–4087
Shapiro B, Sisson JC, Shulkin BL, Gross MD, Zempel S (1995) The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors. Q J Nucl Med 39(4 Suppl 1):3–8
Esfandiari NH, Shulkin BL, Bui C, Jaffe CA (2006) Multimodality imaging of malignant pheochromocytoma. Clin Nucl Med 31(12):822–825
Khorram-Manesh A, Ahlman H, Nilsson O et al (2005) Long-term outcome of a large series of patients surgically treated for pheochromocytoma. J Intern Med 258(1):55–66
Modlin IM, Farndon JR, Shepherd A et al (1979) Phaeochromocytomas in 72 patients: clinical and diagnostic features, treatment and long term results. Br J Surg 66(7):456–465
Schuttler J, Westhofen P, Kania U, Ihmsen H, Kammerecker S, Hirner A (1995) Quantitative assessment of catecholamine secretion as a rational principle of anesthesia management in pheochromocytoma surgery. Anasthesiol Intensivmed Notfallmed Schmerzther 30(6):341–349
Lebuffe G, Dosseh ED, Tek G et al (2005) The effect of calcium channel blockers on outcome following the surgical treatment of phaeochromocytomas and paragangliomas. Anaesthesia 60(5):439–444
Prys-Roberts C (2000) Phaeochromocytoma – recent progress in its management. Br J Anaesth 85(1):44–57
Steinsapir J, Carr AA, Prisant LM, Bransome ED Jr (1997) Metyrosine and pheochromocytoma. Arch Intern Med 157(8):901–906
Elliott HL, Meredith PA, Vincent J, Reid JL (1986) Clinical pharmacological studies with doxazosin. Br J Clin Pharmacol 21(Suppl 1):27S–31S
Bravo EL (1997) Pheochromocytoma. Curr Ther Endocrinol Metab 6:195–197
Mannelli M (2006) Management and treatment of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073:405–416
Pacak K (2007) Preoperative management of the pheochromocytoma patient. J Clin Endocrinol Metab 92(11):4069–4079
Kinney MA, Narr BJ, Warner MA (2002) Perioperative management of pheochromocytoma. J Cardiothorac Vasc Anesth 16(3):359–369
Kanto JH (1985) Current status of labetalol, the first alpha- and beta-blocking agent. Int J Clin Pharmacol Ther Toxicol 23(11):617–628
Thompson GB, Grant CS, van Heerden JA et al (1997) Laparoscopic versus open posterior adrenalectomy: a case-control study of 100 patients. Surgery 122(6):1132–1136
Ippolito G, Palazzo FF, Sebag F, Thakur A, Cherenko M, Henry JF (2008) Safety of laparoscopic adrenalectomy in patients with large pheochromocytomas: a single institution review. World J Surg 32(5):840–844
Soon PS, Yeh MW, Delbridge LW et al (2008) Laparoscopic surgery is safe for large adrenal lesions. Eur J Surg Oncol 34(1):67–70
Jansson S, Khorram-Manesh A, Nilsson O et al (2006) Treatment of bilateral pheochromocytoma and adrenal medullary hyperplasia. Ann N Y Acad Sci 1073:429–435
Yip L, Lee JE, Shapiro SE et al (2004) Surgical management of hereditary pheochromocytoma. J Am Coll Surg 198(4):525–534; discussion 534–525
Amar L, Servais A, Gimenez-Roqueplo AP, Zinzindohoue F, Chatellier G, Plouin PF (2005) Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90(4):2110–2116
Huang H, Abraham J, Hung E et al (2008) Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients. Cancer 113(8):2020–2028
Gedik GK, Hoefnagel CA, Bais E, Valdes Olmos RA (2008) (131)I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 35(4):725–733
Scholz T, Eisenhofer G, Pacak K, Dralle H, Lehnert H (2007) Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92(4):1217–1225
Fitzgerald PA, Goldsby RE, Huberty JP et al (2006) Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 1073:465–490
Yu L, Fleckman AM, Chadha M, Sacks E, Levetan C, Vikram B (1996) Radiation therapy of metastatic pheochromocytoma: case report and review of the literature. Am J Clin Oncol 19(4):389–393
Forrer F, Riedweg I, Maecke HR, Mueller-Brand J (2008) Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma. Q J Nucl Med Mol Imaging 52(4):334–340
Astuti D, Latif F, Dallol A et al (2001) Gene mutations in the succinate dehydrogenase subunit SDHB cause susceptibility to familial pheochromocytoma and to familial paraganglioma. Am J Hum Genet 69(1):49–54
Niemann S, Muller U (2000) Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 26(3):268–270
Baysal BE, Ferrell RE, Willett-Brozick JE et al (2000) Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. Science 287(5454):848–851
Mannelli M, Simi L, Gagliano MS et al (2007) Genetics and biology of pheochromocytoma. Exp Clin Endocrinol Diabetes 115(3):160–165
Yeh IT, Lenci RE, Qin Y et al (2008) A germline mutation of the KIF1B beta gene on 1p36 in a family with neural and nonneural tumors. Hum Genet 124(3):279–285
Carney JA, Stratakis CA (2002) Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet 108(2):132–139
Pasini B, McWhinney SR, Bei T et al (2008) Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet 16(1):79–88
Maher ER, Yates JR, Harries R et al (1990) Clinical features and natural history of von Hippel-Lindau disease. Q J Med 77(283):1151–1163
Friedrich CA (1999) Von Hippel-Lindau syndrome. A pleomorphic condition. Cancer 86(11 Suppl):2478–2482
Lonser RR, Glenn GM, Walther M et al (2003) von Hippel-Lindau disease. Lancet 361(9374):2059–2067
Maher ER, Kaelin WG Jr (1997) von Hippel-Lindau disease. Medicine (Baltimore) 76(6):381–391
Gagel RF, Tashjian AH Jr, Cummings T et al (1988) The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. An 18-year experience. N Engl J Med 318(8):478–484
Modigliani E, Vasen HM, Raue K et al (1995) Pheochromocytoma in multiple endocrine neoplasia type 2: European study. The Euromen Study Group. J Intern Med 238(4):363–367
Chevinsky AH, Minton JP, Falko JM (1990) Metastatic pheochromocytoma associated with multiple endocrine neoplasia syndrome type II. Arch Surg 125(7):935–938
Karagiannis A, Mikhailidis DP, Athyros VG, Harsoulis F (2007) Pheochromocytoma: an update on genetics and management. Endocr Relat Cancer 14(4):935–956
Gutmann DH, Aylsworth A, Carey JC et al (1997) The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA 278(1):51–57
Neumann HP, Pawlu C, Peczkowska M et al (2004) Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292(8):943–951
Gimenez-Roqueplo AP, Lehnert H, Mannelli M et al (2006) Phaeochromocytoma, new genes and screening strategies. Clin Endocrinol (Oxf) 65(6):699–705
Mannelli M, Ercolino T, Giache V, Simi L, Cirami C, Parenti G (2007) Genetic screening for pheochromocytoma: should SDHC gene analysis be included? J Med Genet 44(9):586–587
Benn DE, Richardson AL, Marsh DJ, Robinson BG (2006) Genetic testing in pheochromocytoma- and paraganglioma-associated syndromes. Ann N Y Acad Sci 1073:104–111
Matyakhina L, Bei TA, McWhinney SR et al (2007) Genetics of carney triad: recurrent losses at chromosome 1 but lack of germline mutations in genes associated with paragangliomas and gastrointestinal stromal tumors. J Clin Endocrinol Metab 92(8):2938–2943
Carney JA (1999) Gastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrence. Mayo Clin Proc 74(6):543–552
Gelato MC, Vassalotti J (1990) Insulin-like growth factor-II: possible local growth factor in pheochromocytoma. J Clin Endocrinol Metab 71(5):1168–1174
Lam KY, Lo CY, Wat NM, Luk JM, Lam KS (2001) The clinicopathological features and importance of p53, Rb, and mdm2 expression in phaeochromocytomas and paragangliomas. J Clin Pathol 54(6):443–448
Clarke MR, Weyant RJ, Watson CG, Carty SE (1998) Prognostic markers in pheochromocytoma. Hum Pathol 29(5):522–526
Geli J, Nord B, Frisk T et al (2005) Deletions and altered expression of the RIZ1 tumour suppressor gene in 1p36 in pheochromocytomas and abdominal paragangliomas. Int J Oncol 26(5):1385–1391
Benn DE, Dwight T, Richardson AL et al (2000) Sporadic and familial pheochromocytomas are associated with loss of at least two discrete intervals on chromosome 1p. Cancer Res 60(24):7048–7051
Schlisio S, Kenchappa RS, Vredeveld LC et al (2008) The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev 22(7):884–893
Dahia PL (2006) Transcription association of VHL and SDH mutations link hypoxia and oxidoreductase signals in pheochromocytomas. Ann N Y Acad Sci 1073:208–220
Thouennon E, Elkahloun AG, Guillemot J et al (2007) Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy. J Clin Endocrinol Metab 92(12):4865–4872
Brouwers FM, Elkahloun AG, Munson PJ et al (2006) Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 1073:541–556
Favier J, Briere JJ, Strompf L et al (2005) Hereditary paraganglioma/pheochromocytoma and inherited succinate dehydrogenase deficiency. Horm Res 63(4):171–179
Rustin P, Munnich A, Rotig A (2002) Succinate dehydrogenase and human diseases: new insights into a well-known enzyme. Eur J Hum Genet 10(5):289–291
Semenza GL (2007) Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007(407):cm8
Lee S, Nakamura E, Yang H et al (2005) Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8(2):155–167
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Meyer-Rochow, G.Y., Sidhu, S.B. (2010). Pheochromocytoma and Paraganglioma. In: Sturgeon, C. (eds) Endocrine Neoplasia. Cancer Treatment and Research, vol 153. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-0857-5_9
Download citation
DOI: https://doi.org/10.1007/978-1-4419-0857-5_9
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4419-0856-8
Online ISBN: 978-1-4419-0857-5
eBook Packages: MedicineMedicine (R0)